GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poxel SA (LTS:0RA2) » Definitions » Price-to-Funds-From-Operations

Poxel (LTS:0RA2) Price-to-Funds-From-Operations : (As of Apr. 27, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Poxel Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Poxel Business Description

Industry
Traded in Other Exchanges
Address
259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.